• Health & Medicine

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

13 September 2022

• Health & Medicine
• Science & Technology

How erectile dysfunction drugs could be the key to overcoming treatment resistance in oesophageal cancer

Researchers have found a drug that targets the tumour microenvironment that could improve treatment for certain cancers. But it might not be the kind of drug you expect.  Researchers have found a drug that targets the tumour microenvironment that could improve treatment for certain cancers. But it might not be the kind of drug you expect. 

21 June 2022

• Health & Medicine

Cannabis, cannabinoids and cancer – the evidence so far

The current consensus is that, right now, there isn’t a large enough body of evidence to prove that cannabis (or any of its active compounds or derivatives) can reliably treat any form of cancer but the medical use of cannabis to treat cancer-related chronic pain is approved in the UK. The current consensus is that, right now, there isn’t a large enough body of evidence to prove that cannabis (or any of its active compounds or derivatives) can reliably treat any form of cancer but the medical use of cannabis to treat cancer-related chronic pain is approved in the UK.

13 May 2022

• Health & Medicine

Immune cell count could determine whether chemotherapy is required in oropharyngeal cancer, new study finds 

A new study has found that the level of a person's immune cells may provide an indication of whether they would benefit from chemotherapy in oropharyngeal cancer. A new study has found that the level of a person's immune cells may provide an indication of whether they would benefit from chemotherapy in oropharyngeal cancer.

2 May 2022

• For Researchers

A new approach to cancer immunotherapy

Forty years ago, hints of a new component of the immune system caused a stir. Here, we chart the story of gamma delta T cells from discovery to clinical trials... Forty years ago, hints of a new component of the immune system caused a stir. Here, we chart the story of gamma delta T cells from discovery to clinical trials...

18 March 2022

• Health & Medicine

Aromatase inhibitors cut breast cancer recurrence in younger patients

A study by Oxford University has found that aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in both younger and older women. A study by Oxford University has found that aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in both younger and older women.

11 February 2022

• Science & Technology
• Health & Medicine

Diving into our role in 50 top cancer drugs

To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities' that led to many of the drugs in use today. To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities' that led to many of the drugs in use today.

9 February 2022

• Health & Medicine

Immunotherapy treatment fast tracked to treat lung cancer patients in England

Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England. Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England.

28 January 2022

• Health & Medicine

New breast and lung cancer treatments approved in Scotland

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer. 3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

19 January 2022

• Health & Medicine

New lung cancer treatment combo approved on NHS in England

A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE). A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).

12 January 2022

• Science & Technology
• Health & Medicine

Prising open the trap: Getting to grips with targeted cancer drug resistance

Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding. Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding.

10 January 2022

• Health & Medicine

Immunotherapy approved for some people with advanced melanoma in England

The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer. The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer.

21 December 2021